

***Annals of Translational Medicine* is indexed in PubMed**

Grace Li

Editorial Office, *Annals of Translational Medicine*, Guangzhou 510120, China

Correspondence to: Grace Li, Executive Editor. Editorial Office, *Annals of Translational Medicine*, Guangzhou 510120, China. Email: editor@atmjjournal.org.

Submitted Sep 15, 2014. Accepted for publication Sep 15, 2014.

doi: 10.3978/j.issn.2305-5839.2014.09.08

View this article at: <http://dx.doi.org/10.3978/j.issn.2305-5839.2014.09.08>

On September 5, 2014, an email arrived from beyond the oceans to tell us that *Annals of Translational Medicine* (*Ann Transl Med*; *ATM*; Print ISSN 2305-5839; Online ISSN 2305-5847) has been officially covered in PubMed. Successful coverage in the prestigious PubMed database may mean recognition of *ATM* by international peers, and a closer move towards the master publication list of Science Citation Index (SCI)-indexed journals.

As a joke, friends would like to say, at first glance, *ATM* is easily associated with “automatic teller machine” and then naturally comes the topic about money. Well, it is not a bad association but the journal *ATM* indicates a significant mission.

The *ATM* is an international, peer-reviewed open access journal featuring original and observational investigations in the broad fields of laboratory, clinical, and public health research, aiming to provide practical up-to-date information significant research from all subspecialties of medicine and to broaden the readers’ vision and horizon from bench to bed and bed to bench.

Why we have chosen to focus on translational medicine could be boiled down to the expectation for the future development of medicine and maybe it is worth more investment of dedication and effort than any other areas.

By definition, translational medicine (also referred as translational science) is a discipline within biomedical and public health research that aims to improve the health of individuals and the community by “translating” findings into diagnostic tools, medicines, procedures, policies and education (1).

Retrospectively, the rise of translational medicine is just within a few years’ time and it seems not yet to become quite a spotlight though a few themed conferences held around it and some relevant institutes were established.

The process of translational medicine is explained differently by researchers from different disciplines (2)

(*Figure 1*). The president of American Society of Clinical Oncology (ASCO), Prof. Peter Yu has once provided his views on translational science during his attendance to Chinese Society of Clinical Oncology (CSCO) 2013, “*I think that the translation of science is very sophisticated. That laboratory questions have been asked and with high quality lab work shows deep understanding of the translation of science*” (3).

With a view to bridge the existing gaps between clinicians and researchers and health policy makers, *ATM* was born as a quarterly journal in the spring of 2013 and humbly it grows, yet *ATM* has never missed the so much support and input worldwide. In 2014, *ATM* was released monthly. In this regard, we are grateful to our Editorial Board Members, Guest Editors, authors and reviewers who have contributed to make a difference at *ATM*, and to our audience who has delivered constructive opinions to make *ATM* more readable and relevant.

To expedite the translation of scientific discovery into new or improved standards of management and health outcomes practice, *ATM* covers a broad range of aspects, including multimodality therapy, epidemiology, biomarkers, imaging, biology, pathology, and technical advances related to medicine.

As introduced, one of the focuses of *ATM* is on public health. In July 2014, *ATM* published a special issue on cancer pattern in China (July 2014 issue of *ATM*) and opened a discussion on the topic. This topic is originated from an important work entitled “Report of cancer incidence and mortality in China, 2010”, which is authored by Dr. Wanqing Chen from National Central Cancer Registry, National Cancer Center, China.

Subsequently, experts from different countries were invited to give their own perspectives on cancer registries based on region difference. They include Prof. Stefano Rosso, chairman of the European Network of Cancer Registries (ENCR); Prof. Joannie Lortet-Tieulent from




Figure 1 Process of translational medicine from different researchers’ perspective. Reprinted with permission from Yao N. Health Services & Policy Research in translational medicine. *Ann Transl Med* 2014;2:72.

Table 1 Special issues that were published			
Volume	Topic	Guest editor	Unit
V2N2	Beta-glucan	Vaclav Vetvicka	University of Louisville, Department of Pathology, 511 S. Floyd, Louisville, KY 40202, USA.
V2N3	Endoscopy therapy in the Japanese State and perspectives	Hajime Isomoto, Kazuhiko Nakao	Department of Endoscopy, Nagasaki University Hospital, Nagasaki, Japan.
V2N4	the 7th H-CEO Annual Conference in China	Gianfranco Alpini	Medicine and Systems Biology and Translational Medicine, Central Texas Veterans Health Care System, Scott & White and Texas A & M Health Science Center, College of Medicine.
V2N6	New insights into metformin	Min Shen	Executive Editor, <i>Annals of Translational Medicine</i> .
V2N7	Cancer pattern in China	Gianfranco Alpini	Medicine and Systems Biology and Translational Medicine, Central Texas Veterans Health Care System, Scott & White and Texas A & M Health Science Center, College of Medicine.
V2N8	Translational stroke	Wei-Hai Xu	Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
V2N9	Galectin	Everardo Cobos	Hematology/Oncology Division, Texas Tech University Health Sciences Center, School of Medicine Lubbock, Texas.

American Cancer Society; Prof. David Roder from Cancer Epidemiology & Population Health, University of South Australia; Prof. Lihua Liu, Director of Data Utilization, Los Angeles Cancer Surveillance Program; Prof. Kota Katanoda from Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center and other illustrious experts from China, Japan and UK etc.

The collection of commentaries from different countries has provided a critical and interesting review on the cancer registries.

Since its launch in 2013, *ATM* has gone through 11 issues, 6 of which are special issues on different topics (*Table 1*). This

is accomplished through the unique and innovative format of each published issue. Each special issue entails around 10 international contributors and is thoroughly explored through categorized sections. The future issues of *ATM* are also in plan (*Table 2*).

The rapid exchange of up-to-date knowledge and information in the platform of *ATM* is realized through novel media, using a web-based, digital format in addition to traditional print-version.

For further exposure of the excellent articles from *ATM*, we will invite the international experts to write commentaries on them and highlight these articles in Chinese. The website (<http://www.atmjnjournal.org>) will serve

Table 2 Special issues that are in plan

Volume	Topic
V2N10	Circulation tumor cells
V2N11	Frontiers in drug development
V2N12	Orthopedic surgery
V3N1	Helicobacter pylori
V3N2	MET
V3N3	Diabetes
V3N4	Glioma
V3N5	Cardiovascular disease in autoimmune rheumatic diseases

as the central hub and will be linked to a number of national websites (e.g., kysj.amegroups.com, www.dxy.cn), which will significantly expand the distribution of its contents.

Cite this article as: Li G. Annals of Translational Medicine is indexed in PubMed. Ann Transl Med 2014;2(9):84. doi: 10.3978/j.issn.2305-5839.2014.09.08

The inclusion of *ATM* in PubMed heralds a new beginning! We are confident in achieving new progress with the consistent backup from our friends.

Acknowledgements

Disclosure: The author declares no conflict of interest.

References

1. Available online: http://en.wikipedia.org/wiki/Translational_medicine
2. Yao N. Health Services & Policy Research in translational medicine. Ann Transl Med 2014;2:72.
3. Li GS. Prof. Peter Yu: opportunities and challenges in big data era. Chin Clin Oncol 2014;3:9.